Innovative Industrial Properties Inc., the real estate investment trust that owns cannabis cultivation and processing facilities, posted second-quarter 2026 profit that topped Wall Street estimates even as tenant defaults kept a lid on revenue growth, according to an Aug. 3 SEC filing.
Total revenue was $63.3 million, roughly flat with $62.9 million a year earlier and short of the $67.51 million analysts had projected. Net income attributable to common stockholders, however, jumped to $40.7 million, or $1.36 per diluted share, from $25.1 million, or $0.86 per share, in the second quarter of 2025 β comfortably ahead of the $1.05 per share Wall Street estimate. Funds from operations came in at $47.6 million, or $1.64 per diluted share, while adjusted funds from operations reached $53.0 million, or $1.83 per share.
The board declared a quarterly dividend of $1.90 per common share, a $7.60 annualized rate. The company has now distributed more than $1.2 billion in common stock dividends since its inception, a track record it has maintained through a period of significant turbulence in the state-legal cannabis industry it primarily serves.
That turbulence showed up directly in the quarter’s tenant relationships. PharmaCann, one of IIP’s cannabis operator tenants, paid just $1.2 million in rent during the quarter, though courts released an additional $0.9 million in previously escrowed rent to the REIT. PharmaCann surrendered its Ohio property back to IIP in April 2026, but the company moved quickly to backfill the space, executing a new 58,000-square-foot full-building lease with Curaleaf in Buckeye Lake, Ohio, immediately after regaining possession.
A second tenant, 4Front, remains in receivership affecting four IIP properties totaling 488,000 square feet across Illinois, Washington and Massachusetts. The company said it has reached tentative arrangements with prospective replacement tenants for those assets, with the receivership expected to conclude by the end of 2026.
Away from its core cannabis portfolio, IIP fully funded a $270 million strategic investment in IQHQ, a life science real estate platform, consisting of a $100 million revolving credit facility and $170 million in Series G preferred equity. The company funded $120 million of that preferred equity commitment during the second quarter, which generated $8.5 million in interest and dividend income β a diversification move that gives IIP exposure to the life sciences lab and research space sector alongside its traditional cannabis-industrial holdings.
“Our second quarter activity reflects continued strategy execution … we believe we are well positioned to pursue attractive, accretive growth opportunities,” Executive Chairman Alan Gold said in the earnings release.
The company’s balance sheet remained conservative by REIT standards: net debt stood at just 14.2% of $3.0 billion in gross assets, with $299.7 million in total liquidity and net debt to adjusted EBITDA of 1.7 times.
What it means
IIP’s results illustrate the split reality facing cannabis-focused real estate: individual tenant defaults continue to erode revenue growth even as the company’s disciplined balance sheet and rapid re-tenanting β replacing PharmaCann with Curaleaf in the same quarter it lost the tenant β limit the damage to profitability. The beat-and-raise net income figure, driven partly by gains on asset sales and the IQHQ investment income rather than core rental growth, suggests the REIT is increasingly diversifying away from single-tenant cannabis risk even as it continues managing distress within that legacy portfolio.
The 4Front receivership remains the bigger swing factor for the second half of the year: nearly half a million square feet across three states hangs on whether IIP can convert its tentative new-tenant arrangements into signed leases before the receivership concludes. With liquidity near $300 million and leverage low relative to the broader REIT sector, IIP has the balance sheet capacity to absorb further tenant turnover, but sustained revenue growth will likely require either a recovery in cannabis operator health or continued diversification into adjacent sectors like life sciences.
What to watch: whether IIP successfully converts its tentative 4Front replacement-tenant arrangements into signed leases before year-end, and whether further capital gets deployed into non-cannabis assets like IQHQ as the company diversifies its tenant base.
Related coverage: Alexandria Real Estate Posts Q2 Loss on Impairments as 2026 Guidance Holds · Macerich Reports Record $919 Sales Per Square Foot in Q2 2026 as Net Loss Narrows · Ares Commercial Real Estate Closes $130M in New Loans, Posts Q2 Profit
